Search the webpage

Category: Custom R&D Projects
Animals used for research:  Mouse, Rabbit, Rat 

Experimentica’s Research & Development Division is actively developing novel in vivo models for a number of indications. Some of our current activities include the development of artificial corneas for permeability screening, development of standardized and validated readouts in novel models for diabetic retinopathy, identification of pathophysiological processes in meibomain gland dysfunction, and innovative approaches to induce demyelination of the optic nerve to mimic optic neuritis.

Utilizing state-of-the-art technology for the longitunial in vivo imaging of ocular tissues, such as spectral-domain ocular coherence tomography, fluorescein angiography and vitreofluorophometry, paired with traditional histological and molecular readout, we are able to detect early patholofical changes with unprecedented accuracy.

We look forward to an opportunity to partner with you to refine or develop almost any custom in vivo project. Over the years, we have worked with numerous pharmaceutical and biotech companies and academic institutions to either implement models previously described in the scientific literature or to develop novel models for ophthalmic disease indications.

SUMMARY

Animal species

Mouse, Rabbit, Rat.

Method of induction

Chirurgical or mechanical damage, lasering, intravitreal or subretinal injections of specialized compounds, exposure to external factors.

Follow-up period

Up to 12 months.

Route of compound administration

Topical, intravitreal injection, intravenous, systemic.

Read-outs

1. In vivo imaging:
fundoscopy;
fluorescein angiography;
optical coherence tomography (OCT);
vitreofluorophotometry.

 

2. In vivo functional assessment (behavioral analysis and scoring, electroretinogram and visually-evoked potentials)

 

3. Morphological assessment (histology, immunohistochemistry, electron microscopy, stereology)

 

4. Molecular biology (ELISA, Western blotting, qPCR)

Please contact us, if you would like to receive more information: info@experimentica.com

IMAGES

Experimentica's Preclinical Development Pipeline

Our Preclinical Development Pipeline allows you to take your drug candidates from mechanistic in vitro studies through preclinical pharmacology to GLP tolerability and toxicology studies.

SELECTED PUBLICATIONS

  • Ragauskas S, Kielczewski E, Vance J, Kaja S, Kalesnykas G. In vivo multimodal imaging and analysis of mouse laser-induced choroidal neovascularization model. J Vis Exp (131), e56173. DOI:10.3791/56173 (2018).
  • Tuomela A, Liu P, Puranen J, Rönkkö S, Laaksonen T, Kalesnykas G, Oksala O, Ilkka J, Laru J, Järvinen K, Hirvonen J, Peltonen L. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo. Int J Pharm. 2014 Jun 5;467(1-2):34-41.

REFERENCES

  • Hakkarainen JJ, Reinisalo M, Ragauskas S, Seppänen A, Kaja S, Kalesnykas G. Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells. International Journal of Pharmaceutics 2016; 511:73-78.
  • Ragauskas S, Leinonen H, Puranen J, Rönkkö S, Nymark S, Gurevicius K, Lipponen A, Kontkanen O, Puoliväli J, Tanila H, Kalesnykas G. Early Retinal Function Deficit without Prominent Morphological Changes in the R6/2 Mouse Model of Huntington’s Disease. PLoS One. 2014 Dec 3;9(12):e113317.

LATEST NEWS

Meet us at SMi’s Ophthalmic Drugs Conference 2019 in London, UK, 2019

News
We are pleased to be a part of the 3rd Annual Ophthalmic Drugs Conference and Focus Day, taking place on ... Read More

Experimentica Ltd. is a member of BioMelbourne Network

News
We are delighted to become a member of BioMelbourne Network together with other committed organisations engaged in biotechnology, medical technology, ... Read More

Let’s meet at Global Biotech VIP Week in Melbourne, 2019

News
Experimentica’s CEO Giedrius Kalesnykas attends Global Biotech VIP Week in Melbourne, Australia, sponsored by Global Victoria, and participates in AusBiotech ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!